In a filing, Denali Therapeutics Inc revealed its Chief Medical Officer Ho Carole unloaded Company’s shares for reported $0.25 million on Jan 06 ’25. In the deal valued at $20.22 per share,12,255 shares were sold. As a result of this transaction, Ho Carole now holds 178,580 shares worth roughly $4.11 million.
Then, Ho Carole sold 2,907 shares, generating $60,495 in total proceeds. Upon selling the shares at $20.81, the Chief Medical Officer now owns 175,673 shares.
Before that, Schuth Alexander O. sold 12,255 shares. Denali Therapeutics Inc shares valued at $247,796 were divested by the COFO and Secretary at a price of $20.22 per share. As a result of the transaction, Schuth Alexander O. now holds 247,215 shares, worth roughly $5.68 million.
Robert W. Baird initiated its Denali Therapeutics Inc [DNLI] rating to an Outperform in a research note published on January 07, 2025; the price target was $31. A number of analysts have revised their coverage, including William Blair’s analysts, who began to cover the stock in early January with a ‘”an Outperform”‘ rating. Stifel also remained covering DNLI and has increased its forecast on December 16, 2024 with a “Buy” recommendation from previously “Hold” rating.
Price Performance Review of DNLI
On Tuesday, Denali Therapeutics Inc [NASDAQ:DNLI] saw its stock jump 5.27% to $22.99. Over the last five days, the stock has lost -2.17%. Denali Therapeutics Inc shares have risen nearly 12.81% since the year began. Nevertheless, the stocks have risen 40.27% over the past one year. While a 52-week high of $33.33 was reached on 01/30/25, a 52-week low of $14.56 was recorded on 01/14/25. SMA at 50 days reached $22.59, while 200 days put it at $23.35.
Levels Of Support And Resistance For DNLI Stock
The 24-hour chart illustrates a support level at 21.99, which if violated will result in even more drops to 21.00. On the upside, there is a resistance level at 23.75. A further resistance level may holdings at 24.51. The Relative Strength Index (RSI) on the 14-day chart is 53.06, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.06, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 26.86%. Stochastics %K at 71.17% indicates the stock is a holding.
How much short interest is there in Denali Therapeutics Inc?
A steep rise in short interest was recorded in Denali Therapeutics Inc stocks on 2025-01-15, growing by 0.5 million shares to a total of 7.97 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-13 was 7.46 million shares. There was a rise of 6.34%, which implies that there is a positive sentiment for the stock.
